Amanote Research
Register
Sign In
Php223 - Trerapeutic Areas, a Key Factor for Hta and Reimbursement Decisions, Timming and Access
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1117
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
J. Ferrer
Publisher
Elsevier BV
Related search
Pnd99 - Cystic Fibrosis Therapies - Key Drivers Behind Differing Hta Decisions
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss46 - Differences in Hta Coverage Recommendations: Comparing Ophthalmology Drug Reimbursement Decisions in Four European Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy184 - Hta and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for Manufacturers?s?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Balancing Early Access With Uncertainties in Evidence for Drugs Authorized by Prospective Case Series - Systematic Review of Reimbursement Decisions
British Journal of Clinical Pharmacology
Pharmacology
Pcn274 - Time to Price Change Following Hta Decisions
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases
Medical Decision Making
Health Policy
EU Payer and Decision Maker Use of Observational Studies for Health Care Reimbursement Decisions
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Reimbursement Decisions in Oncology Drugs: An International Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
